<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Biomol Struct Dyn</journal-id><journal-id journal-id-type="iso-abbrev">J Biomol Struct Dyn</journal-id><journal-title-group><journal-title>Journal of Biomolecular Structure &#x00026; Dynamics</journal-title></journal-title-group><issn pub-type="ppub">0739-1102</issn><issn pub-type="epub">1538-0254</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7544953</article-id><article-id pub-id-type="doi">10.1080/07391102.2020.1808077</article-id><article-id pub-id-type="publisher-id">1808077</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title><italic>In-silico</italic> screening of plant-derived antivirals against main protease, 3CL<sup>pro</sup> and endoribonuclease, NSP15 proteins of SARS-CoV-2</article-title><alt-title alt-title-type="left-running-head">A. Sharma et al.</alt-title><alt-title alt-title-type="right-running-head">Journal of Biomolecular Structure and Dynamics</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Aniket</given-names></name><xref ref-type="aff" rid="AF0001">a</xref><xref ref-type="author-notes" rid="EN0002">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Goyal</surname><given-names>Shubham</given-names></name><xref ref-type="aff" rid="AF0001">a</xref><xref ref-type="author-notes" rid="EN0002">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Yadav</surname><given-names>Arvind Kumar</given-names></name><xref ref-type="aff" rid="AF0002">b</xref></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Pawan</given-names></name><xref ref-type="aff" rid="AF0003">c</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2610-3142</contrib-id><name><surname>Gupta</surname><given-names>Lovely</given-names></name><xref ref-type="aff" rid="AF0001">a</xref><xref ref-type="corresp" rid="AN0001"/></contrib><aff id="AF0001"><label>a</label><institution>Amity Institute of Biotechnology, Amity University</institution>, <city>Noida</city>, <state>Uttar Pradesh</state>, <country>India</country></aff><aff id="AF0002"><label>b</label><institution>Department of Biotechnology and Bioinformatics, Jaypee University of Information Technology</institution>, <city>Solan</city>, <state>Himachal Pradesh</state>, <country>India</country></aff><aff id="AF0003"><label>c</label><institution>Bioinformatics Centre, National Institute of Immunology</institution>, <city>New Delhi</city>, <country>India</country></aff></contrib-group><author-notes><fn id="AUFN1"><p>Supplemental data for this article can be accessed online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/07391102.2020.1808077">https://doi.org/10.1080/07391102.2020.1808077</ext-link>.</p></fn><fn id="EN0002"><label><sup>&#x02020;</sup></label><p>Authors contributed equally in the research work.</p></fn><corresp id="AN0001"><bold>CONTACT</bold> Lovely Gupta <email xlink:href="mailto:lgupta@amity.edu">lgupta@amity.edu</email><institution>Amity Institute of Biotechnology, Amity University</institution>, <city>Noida</city>, <state>Uttar Pradesh</state><postal-code>201301</postal-code>, <country>India</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>8</day><month>9</month><year>2020</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2020</year></pub-date><fpage seq="1">1</fpage><lpage>15</lpage><permissions><copyright-statement>&#x000a9; 2020 Informa UK Limited, trading as Taylor &#x00026; Francis Group</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Informa UK Limited, trading as Taylor &#x00026; Francis Group</copyright-holder><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="TBSD_0_1808077.pdf"/><abstract><title>Abstract</title><p>Novel Coronavirus or SARS-CoV-2 outbreak has developed a pandemic condition all over the world. The virus is highly infectious and spreads by human to human local transmission mode. Till date, there is no vaccination or drugs been approved for the treatment by the World Health Organisation. Henceforth, the discovery of the potential drugs is an urgent and utmost requirement for the medical fraternity. Since, the side effects of plant-derived compounds will be lower compared to synthetic/chemical drugs. The Main protease (3CL<sup>pro</sup> or NSP5) and endoribonuclease (NSP15) proteins are necessity for viral replication and its survival in the host cell. In the present study, <italic>in-silico</italic> approach of drug development was used to search for potential antiviral plant-derived compounds as inhibitors against SARS-CoV-2 replication proteins. Eight plant-derived compounds of which the antiviral activity was known and available, and two reported drugs against SARS-CoV-2 selected for the molecular docking analysis. The docking results suggested that bisdemethoxycurcumin, demethoxycurcumin, scutellarin, quercetin and myricetin showed least binding energy, <italic>i.e.,</italic> greater than &#x02212;6.5&#x02009;Kcal/mol against 3CL<sup>pro</sup> and endoribonuclease of SARS-CoV-2. Further studies of ADME-Tox and bioavailability of drugs were also performed that exhibited efficient parameters of drug likeness. Molecular dynamics simulation calculations were performed for the most negative binding affinity of the compound to evaluate the dynamic behavior,and stability of protein-ligand complex. Our findings suggest that these compounds could be potential inhibitors of SARS&#x02010;CoV-2 main protease and endoribonuclease. However, further <italic>in-vitro</italic> and pre-clinical experiments would validate the potential inhibitors of SARS&#x02010;CoV&#x02010;2 proteins.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>SARS-CoV-2</kwd><kwd>COVID-19</kwd><kwd>docking</kwd><kwd>plant-derived compounds</kwd><kwd>3CL<sup>pro</sup></kwd><kwd>endoribonuclease</kwd></kwd-group><counts><fig-count count="8"/><table-count count="4"/><page-count count="15"/><word-count count="7729"/></counts></article-meta></front><body><sec sec-type="intro" id="S0001" disp-level="1"><title>Introduction</title><p>A mysterious breakdown of typical pneumonia by a novel coronavirus (COVID-19), created a pandemic situation all over the world by spreading the disease named as severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) by the World Health Organization (WHO). This disease is more contagious than previous outbreaks of severe acute respiratory syndrome (SARS) in the year 2002 and the Middle East respiratory syndrome (MERS) in 2012 (Dhama et&#x000a0;al., <xref rid="CIT0010" ref-type="bibr">2020</xref>; Guo et&#x000a0;al., <xref rid="CIT0018" ref-type="bibr">2020</xref>). By the end of the year 2019, an outbreak from COVID-19 occurred in Wuhan, Hubei Province of China. It was reported to infect over 3.3 million people and killed more than 0.23 million people in around 215 countries as of May 03, 2020 (<ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019">https://www.who.int/emergencies/diseases/novel-coronavirus-2019</ext-link>). According to WHO situation report-71, India reported 1071 positive cases of SARS-CoV-2 and after one month, WHO situation report-99 reported 29435 positive cases of coronavirus affected patients. India&#x02019;s death rate of COVID-19 is still lower than the global death rate of around 3.4 percent, according to data and statistics website worldometer (<ext-link ext-link-type="uri" xlink:href="https://www.worldometers.info/coronavirus/">https://www.worldometers.info/coronavirus/</ext-link>).</p><p>SARS-CoV-2 is considered to be a seventh known human coronavirus (hCoV) from the same family after 229E, NL63, OC43, HKU1, MERS-CoV and SARS-CoV that belongs to the &#x003b2;-coronavirus family (<italic>coronaviridae</italic>). It contains a single-stranded positive-sense (+) RNA encapsulated within the lipid membrane. It has been reported that the genome of SARS-CoV-2 was 96.2%, 79%, and 50% nucleotide identical with bat-CoV RaTG13, SARS-CoV, and MERS genome, respectively (Dhama et&#x000a0;al., <xref rid="CIT0010" ref-type="bibr">2020</xref>; Guo et&#x000a0;al., <xref rid="CIT0018" ref-type="bibr">2020</xref>). Therefore, the bat was suspected to be a natural host of virus origin that infected human via pangolins (<italic>Manisjavanica)</italic> as an intermediate host.</p><p>The genome of SARS-CoV-2 is divided into two parts: open reading frames (ORFs) that encode accessory and structural proteins; and non-structural proteins (NSP). Structural protein involves spike (S) glycoprotein, small envelope (E) protein, matrix (M) protein, and nucleocapsid (N) protein (Boopathi et&#x000a0;al., <xref rid="CIT0004" ref-type="bibr">2020</xref>). Sixteen NSP&#x02019;s are known to encode various enzymes required for replication and transcription process such as main protease (NSP5 and NSP3), RNA dependent-RNA polymerase (NSP12), a helicase/triphosphatase (NSP13), an exoribonuclease (NSP14), an endonuclease (NSP15) (Chan et&#x000a0;al., <xref rid="CIT0005" ref-type="bibr">2020</xref>). Studies have proved that protein NSP15 of SARS-CoV-2 has 88% and &#x0223c;50% sequence identity, 95% and 65% similarity with SARS-CoV and MERS, respectively (Kim et&#x000a0;al., <xref rid="CIT0027" ref-type="bibr">2020</xref>). NSP15 protein, an endoribonuclease, one of the crucial NSP for viral replication and transcription. It is highly conserved in all known CoVs (Hackbart et&#x000a0;al., <xref rid="CIT0020" ref-type="bibr">2020</xref>). It is a nidoviral RNA uridylate-specific (NendoU) endoribonuclease containing 346 amino acid and made up of 2 domains NSP-15A1 and NSP-15B. It is an interferon (IFN) antagonist and inhibits interferon-&#x003b2; production via an endoribonuclease activity-independent mechanism. (Liu et&#x000a0;al., <xref rid="CIT0033" ref-type="bibr">2019</xref>)</p><p>There are two proteases encoded in the SARS-CoV-2 RNA strand: papain-like protease (PL<sub>P</sub> or NSP3) and 3-Chymotrypsin-like protease (3CL<sup>pro</sup> or NSP5) co-translationally cleave the two polypeptides into mature NSPs (Lim et&#x000a0;al., <xref rid="CIT0031" ref-type="bibr">2000</xref>). The 3CL<sup>pro</sup>, also known as M<sub>pro</sub>, has a dominant role in the post-translational processing of the replicase gene. Protease M<sub>pro</sub> has been reported to be a conserved protein, in favour of new drug target in (+) strand coronaviruses (Chandel et&#x000a0;al., <xref rid="CIT0007" ref-type="bibr">2020</xref>). It has two homodimer NSP5A and NSP5B. It belongs to the cysteine protease class of protein and responsible for the cleavage of viral peptides into functional units for replication and packaging within the host cells (Liu et&#x000a0;al., <xref rid="CIT0032" ref-type="bibr">2020</xref>). It is produced by ORF pp1ab only. Targeting M<sub>pro</sub> enzyme will inhibit the viral maturation and enhance the host innate immune response against COVID-19 (Elmezayen et&#x000a0;al., <xref rid="CIT0013" ref-type="bibr">2020</xref>). Other studies suggested that the sequence similarity of NSP5 of SARS-CoV-2 reported nearly 95% with SARS-CoV (Chan et&#x000a0;al., <xref rid="CIT0005" ref-type="bibr">2020</xref>). In the current study, two protein targets (3CL<sup>pro</sup> and endoribonuclease) of SARS-CoV-2 selected based on conserved sequence and their importance in virus replication according to the literature.</p><p>For the treatment of COVID-19, doctors are prescribing antimalarial, anti-HIV, anti-influenza drugs and their combinations, but these drugs are not permanent cure of coronavirus infection (Joshi et&#x000a0;al., <xref rid="CIT0025" ref-type="bibr">2020</xref>). Drugs such as Hydroxychloroquine, Chloroquine, Nelfinavir, Rhein, Withaferin A, Withanolide D, Enoxacin, Mercaptopurine and Aloe-emodin are tested against various target proteins of viruses (Muralidharan et&#x000a0;al., <xref rid="CIT0038" ref-type="bibr">2020</xref>). Conversely, various phytochemicals reported in the literature to possess potential anti-viral activity that could be an alternative to restrict the coronavirus replication (Elfiky, <xref rid="CIT0012" ref-type="bibr">2020</xref>). Natural compounds consist of high chemical diversity, lower cost of production than that of biotechnological products or compounds synthesised from combinatorial chemistry and also possess milder or inexistent side effects than chemical drugs (Kitazato et&#x000a0;al., <xref rid="CIT0029" ref-type="bibr">2007</xref>). Therefore, in the present study attempt has been made to screen and evaluate the plant-derived compounds that have therapeutic applications against different genetically and functionally diverse viruses using molecular docking study.</p></sec><sec sec-type="materials" id="S0002" disp-level="1"><title>Material and method</title><sec id="S0002-S2001" disp-level="2"><title>Retrieval of the target structure and their preparation</title><p>The protein structure of 3-chymotrypsin-like cysteine protease (3CL<sup>pro</sup>) enzyme (PDB ID: 6LU7) with 2.1&#x000c5; resolution and endoribonuclease, non-structural protein 15 (NSP15) protein (PDB ID: 6VWW) with 2.2&#x000c5; resolution of SARS-CoV- 2 were downloaded from RCSB protein databank (<ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org">http://www.rcsb.org</ext-link>). Initially, different tasks were performed for protein preparation such as charge assignment, solvation parameters and fragmental volumes using SPDVB-4.10 version (Morris et&#x000a0;al., <xref rid="CIT0036" ref-type="bibr">2009</xref>). The protein molecules were further optimized using AutoDock4 Tool for the molecular docking (Morris et&#x000a0;al., <xref rid="CIT0036" ref-type="bibr">2009</xref>).</p></sec><sec id="S0002-S2002" disp-level="2"><title>Secondary structure prediction</title><p>The secondary structure of proteins was speculated using the Self-Optimized Prediction Method with Alignment (SOPMA) server at <ext-link ext-link-type="uri" xlink:href="https://npsa-prabi.ibcp.fr/cgi-bin/npsa_automat.pl?page=/NPSA/npsa_sopma.html">https://npsa-prabi.ibcp.fr/cgi-bin/npsa_automat.pl?page=/NPSA/npsa_sopma.html</ext-link> (Geourjon &#x00026; Del&#x000e9;age, <xref rid="CIT0017" ref-type="bibr">1995</xref>). SOPMA predicts four conformational states including Helix, Beta sheets and bridges, Turns and Coils for each antigen.</p></sec><sec id="S0002-S2003" disp-level="2"><title>Preparation of ligands</title><p>The natural compounds for the ligand dataset were selected from the previous literature (<xref rid="t0002" ref-type="table">Table 2</xref>). Eight selected natural compounds and two drugs were obtained from the PubChem compound database (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4702940/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4702940/</ext-link>) in InChI (Inch key) format. The two-dimensional (2D) ligand structures were generated using ACD/Chemsketch and save as mol file format. The three-dimensional (3D) structure of ligands were converted using OpenBabel tool (O&#x02019;Boyle et&#x000a0;al., <xref rid="CIT0039" ref-type="bibr">2011</xref>).</p></sec><sec id="S0002-S2004" disp-level="2"><title>Molecular docking</title><p>The docking analysis was performed by molecular docking program AutoDock4 Tool (Morris et&#x000a0;al., <xref rid="CIT0036" ref-type="bibr">2009</xref>) to explore the poses of potential inhibitors within the targets active site. For protein-ligand interactions, the Lamarckian genetic algorithm was utilized to perform the docking with the preset parameters. The total number of poses was set to 50. Poses were further clustered using all atom RMSD cutoff of 0.3&#x02009;&#x000c5; to remove redundancy and on average 20 cluster representatives were kept. All other parameters for docking and scoring were used as default sets. The protein structure was kept rigid in all steps. All the docking poses and interaction analysis has been performed using the UCSF Chimera (Pettersen et&#x000a0;al., <xref rid="CIT0040" ref-type="bibr">2004</xref>) and Discovery Studio Visualizer programs (<ext-link ext-link-type="uri" xlink:href="http://accelrys.com/products/collaborative-science/biovia-discovery-studio/visualization-download.php">http://accelrys.com/products/collaborative-science/biovia-discovery-studio/visualization-download.php</ext-link>). The amino acids residues that displayed interactions with the ligand were documented in <xref rid="t0003" ref-type="table">Table 3</xref> and <xref ref-type="fig" rid="F0001">Figure S1</xref> and <xref ref-type="fig" rid="F0002">S2</xref> (Supplementary material).</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Ribbon structure of (A) 3CL<sup>pro</sup> and (B) NSP15 protein. Crystal structure of (C) 3CL<sup>pro</sup> (PDB-ID:6LU7) and (D) NSP15 endoribonuclease protein (PDB-ID:6VWW). Source- PDB databank.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1808077_F0001_C"/></fig><fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>The predicted secondary structure of the (A) 3CL<sup>pro</sup> and (B) NSP15 endoribonuclease using SOPMA software, whereas h: Alpha helix, e: Extended strand, t: Beta-turn and c: Random coil. The graphical representation of secondary elements in 3CL<sup>pro</sup> and NSP15 endoribonuclease protein (blue: alpha helix, red: extended, green: beta turn, yellow: random coil).</p></caption><graphic content-type="color" xlink:href="TBSD_A_1808077_F0002_C"/></fig></sec><sec id="S0002-S2005" disp-level="2"><title>ADME-Tox prediction</title><p>The qualitative measurement of absorption, distribution, metabolism, excretion, and toxicity profile of selected compounds were predicted by using SwissADME program (<ext-link ext-link-type="uri" xlink:href="http://www.swissadme.ch/index.php">http://www.swissadme.ch/index.php</ext-link>) (Hoda et&#x000a0;al., <xref rid="CIT0021" ref-type="bibr">2019</xref>). The major ADME-Tox properties parameters include Molecular weight, H-bond acceptor, H-bond donors, Predicted octanol/water partition coefficient (MLogP), Total Polar Surface Area (TPSA), Lipinski (drug likeness), GI absorption, BBB permeant, Bioavailability score.</p></sec><sec id="S0002-S2006" disp-level="2"><title>Molecular dynamics simulation setup and analysis</title><p>To analyze the conformational dynamics of the unbound and bound state of 3CL<sup>pro</sup> and endoribonuclease enzyme, molecular dynamics simulation has been performed using the Amber16 package (Gajula et&#x000a0;al., <xref rid="CIT0016" ref-type="bibr">2016</xref>). After the preparation of the docked ligand molecules using the antechamber (Wang et&#x000a0;al., <xref rid="CIT0055" ref-type="bibr">2006</xref>), tleap module is used to prepare the cubic simulation box of size 10&#x02009;&#x000c5; considering the protein at the center, the box was filled with TIP3P water molecules (Jorgensen et&#x000a0;al., <xref rid="CIT0024" ref-type="bibr">1983</xref>) for solvation under periodic boundary condition. Some water molecules were replaced by the counterions to neutralize the systems. The Generalized Amber Force Field (GAFF) for ligand (Wang et&#x000a0;al., <xref rid="CIT0056" ref-type="bibr">2004</xref>) and FF14SB FF for protein (Maier et&#x000a0;al., <xref rid="CIT0035" ref-type="bibr">2015</xref>) was used during the simulation setup. For all electrostatic interactions calculation, Particle Mesh Ewald (PME) method (Essmann et&#x000a0;al., <xref rid="CIT0015" ref-type="bibr">1995</xref>) was used and 2 fs time step is used with the SHAKE algorithm (Ryckaert et&#x000a0;al., <xref rid="CIT0045" ref-type="bibr">1977</xref>) to constrain the hydrogen bonds.</p><p>Prepared simulation box was initially minimized for 500,000 steps (400,000SD +100,000CG) to relax the system. The minimized system was gradually heated from the 0 to 300&#x02009;K over the period of 6000ps. A 1&#x02009;ns simulation run was further used to equilibrate the system under NVT ensemble. The final MD production run of 50&#x02009;ns was performed with an integration time step of 2.0 fs. Simulation conformations were collected after every 50ps and all trajectories were analyzed for the RMSD, RMSF, SASA and hydrogen bond dynamics using the CPPTRAJ module (Roe &#x00026; Cheatham, <xref rid="CIT0044" ref-type="bibr">2013</xref>) of the Amber software.</p></sec></sec><sec sec-type="results" id="S0003" disp-level="1"><title>Results</title><p>To perform the target protein analysis, FASTA sequences and 3&#x02009;D structure of 3CL<sup>pro</sup> and endoribonuclease were retrieved from PDB databank (PDB ID: 6LU7 and 6VWW) (<xref ref-type="fig" rid="F0001">Figure 1</xref>). The secondary structure prediction indicated that protein 3CL<sup>pro</sup> consisted 29.08% &#x003b1;-helix (h), 27.12% extended strand (e), 11.44% beta-turn (t), 32.35% random coil (c) elements and NSP15 endoribonuclease comprised of 24.26% &#x003b1;-helix (h), 26.95% extended strand (e), 9.70% beta-turn (t), 39.08% random coil (c). There are two graphs shown in the result- 1) to visualize the prediction; 2) score curves for all predicted states (<xref ref-type="fig" rid="F0002">Figure 2</xref>). It also shows the parameters such as window width, number of states etc. that are used for the prediction.</p><p>Molecular docking was performed to evaluate the interaction of plant-derived compounds, having reported pharmacological activities against two non-structural proteins of SARS-CoV-2. Non-structural proteins, 3CL<sup>pro</sup> and endoribonuclease were targeted and the docking pocket was formed at the catalytic sites of the respective proteins as mentioned in <xref rid="t0001" ref-type="table">Table 1</xref>. Also, the binding affinity of interacted compounds at the active site were assessed. Known anti-viral drugs such as remdesivir and ribavirin were docked against 3CL<sup>pro</sup> as well as endoribonuclease proteins. Plant-derived active compounds, reported with their pharmacological properties were listed in <xref rid="t0002" ref-type="table">Table 2</xref>.</p><table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Active site residues of 3CL<sup>pro</sup> and NSP15 endoribonuclease protein.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">Protein Site</th><th align="center">Residues</th><th align="center">Amino Acids</th><th align="center">Co-ordinates of amino acid residues</th></tr></thead><tbody valign="top"><tr><td align="left">3CL<sup>pro</sup></td><td align="left">Cys</td><td align="char" char=".">145</td><td align="left">x-axis: 3.032<break/>y-axis: &#x02212;4.728<break/>z-axis: 39.052</td></tr><tr><td align="left">Endoribonuclease (NSP15)</td><td align="left">Thr</td><td align="char" char=".">341</td><td align="left">x-axis: &#x02212;93.206<break/>y-axis: 14.072<break/>z-axis: &#x02212;5.47</td></tr></tbody></table></table-wrap><table-wrap id="t0002" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Selected plant-derived compounds based on their known pharmacological properties.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">S.no.</th><th align="center">Plant-derived compound</th><th align="center">Reported activity</th><th align="center">Disease</th><th align="center">References</th></tr></thead><tbody valign="top"><tr><td align="left">1.</td><td align="left">Curcumin</td><td align="left">Anti-viral</td><td align="left">Herpes virus, Ebola</td><td align="left">(Kutluay et&#x000a0;al.,<xref ref-type="bibr" rid="CIT0030">2008</xref>)</td></tr><tr><td align="left">2.</td><td align="left">Demethoxycurcumin</td><td align="left">Anti-viral</td><td align="left">Ebola</td><td align="left">(Baikerikar,<xref ref-type="bibr" rid="CIT0002">2017</xref>)</td></tr><tr><td align="left">3.</td><td align="left">Bisdemethoxycurcumin</td><td align="left">Anti-viral</td><td align="left">Ebola</td><td align="left">(Baikerikar,<xref ref-type="bibr" rid="CIT0002">2017</xref>)</td></tr><tr><td align="left">4.</td><td align="left">Scutellarin</td><td align="left">Anti-viral</td><td align="left">Covid-19 (Nsp-13)</td><td align="left">(Yu et&#x000a0;al.,<xref ref-type="bibr" rid="CIT0058">2012</xref>)</td></tr><tr><td align="left">5.</td><td align="left">Myricetin</td><td align="left">Anti-inflammatory</td><td align="left">Diabetes mellitus</td><td align="left">(Dorm&#x000e1;n et&#x000a0;al., <xref ref-type="bibr" rid="CIT0011">2016</xref>)</td></tr><tr><td align="left">6.</td><td align="left">Quercetin</td><td align="left">Anti-viral</td><td align="left">Mingo virus, Poliovirus, Herpes small virus-2</td><td align="left">(Veckenstedt et&#x000a0;al.,<xref ref-type="bibr" rid="CIT0052">1987</xref>)</td></tr><tr><td align="left">7.</td><td align="left">Bergapten</td><td align="left">Anti-viral</td><td align="left">Coxsackievirus B3, Herpes small virus-1</td><td align="left">(Rajtar et&#x000a0;al.,<xref ref-type="bibr" rid="CIT0042">2017</xref>)</td></tr><tr><td align="left">8.</td><td align="left">Isoflavone</td><td align="left">Anti-viral</td><td align="left">Herpes small Virus-1</td><td align="left">(Akula et&#x000a0;al.,<xref ref-type="bibr" rid="CIT0001">2002</xref>)</td></tr></tbody></table></table-wrap><table-wrap id="t0003" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Details of molecular docking analysis of Plant-based compounds against SARS-CoV-2 endoribonuclease and 3CL<sup>pro</sup> proteins.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th rowspan="2" align="left">Compound Name</th><th rowspan="2" align="center">PubChem CID</th><th rowspan="2" align="center">Structure</th><th colspan="2" align="center">3CL<sup>Pro</sup><hr/></th><th colspan="2" align="center">Endoribonuclease<hr/></th></tr><tr><th align="center">Binding affinity</th><th align="center">Amino acid residues</th><th align="center">Binding affinity</th><th align="center">Amino acid residues</th></tr></thead><tbody valign="top"><tr><td align="left">Demethoxycurcumin</td><td align="center">5469424</td><td align="center"><inline-graphic xlink:href="TBSD_A_1808077_ILG0001_C.gif" content-type="color"/></td><td align="center">&#x02212;7.02</td><td align="center">His 163</td><td align="center">&#x02212;7.51</td><td align="center">Lys 290; Gly 248; His 235; Thr 341; Glu 340</td></tr><tr><td align="left">Curcumin</td><td align="center">969516</td><td align="center"><inline-graphic xlink:href="TBSD_A_1808077_ILG0002_C.gif" content-type="color"/></td><td align="center">&#x02212;6.04</td><td align="center">Asn 119; His 163</td><td align="center">&#x02212;6.48</td><td align="center">Lys 290</td></tr><tr><td align="left">Bisdemethoxycurcumin</td><td align="center">5315472</td><td align="center"><inline-graphic xlink:href="TBSD_A_1808077_ILG0003_C.gif" content-type="color"/></td><td align="center">&#x02212;7.3</td><td align="center">Cys 145;His 41; His 41; Phe 140; His 163</td><td align="center">&#x02212;6.56</td><td align="center">Lys 290</td></tr><tr><td align="left">Quercetin</td><td align="center">5280343</td><td align="center"><inline-graphic xlink:href="TBSD_A_1808077_ILG0004_C.gif" content-type="color"/></td><td align="center">&#x02212;6.58</td><td align="center">Asn 142; Gly 143; Ser 144; Leu 141; Cys 145; His 41; Thr 26; Thr 26</td><td align="center">&#x02212;6.49</td><td align="center">Lys 290; His 235;His 250; Glu 340</td></tr><tr><td align="left">Myricetin</td><td align="center">5281672</td><td align="center"><inline-graphic xlink:href="TBSD_A_1808077_ILG0005_C.gif" content-type="color"/></td><td align="center">&#x02212;6.15</td><td align="center">Gly 143; Leu 141; His 41; Thr 26</td><td align="center">&#x02212;6.52</td><td align="center">Lys 290; His 235;His 250; Glu 340</td></tr><tr><td align="left">Bergapten</td><td align="center">2355</td><td align="center"><inline-graphic xlink:href="TBSD_A_1808077_ILG0006_C.gif" content-type="color"/></td><td align="center">&#x02212;5.98</td><td align="center">His 163; His 163; Phe 140</td><td align="center">&#x02212;5.92</td><td align="center">Lys 290; His 235;Ser 294; Thr 341</td></tr><tr><td align="left">Scutellarin</td><td align="center">5281697</td><td align="center"><inline-graphic xlink:href="TBSD_A_1808077_ILG0007_C.gif" content-type="color"/></td><td align="center">&#x02212;7.13</td><td align="center">Gly 143; His 163</td><td align="center">&#x02212;6.97</td><td align="center">Lys 290; His 250;Gly 248; Glu 340</td></tr><tr><td align="left">Isoflavone</td><td align="center">72304</td><td align="center"><inline-graphic xlink:href="TBSD_A_1808077_ILG0008_C.gif" content-type="color"/></td><td align="center">&#x02212;5.69</td><td align="center">Gly 143, Cys 145</td><td align="center">&#x02212;5.47</td><td align="center">His 235; Thr 341</td></tr><tr><td align="left">Remdesivir</td><td align="center">121304016</td><td align="center"><inline-graphic xlink:href="TBSD_A_1808077_ILG0009_C.gif" content-type="color"/></td><td align="center">196</td><td align="center">Phe 140; His 164</td><td align="center">&#x02212;7.7</td><td align="center">Glu 340</td></tr><tr><td align="left">Ribavirin</td><td align="center">37542</td><td align="center"><inline-graphic xlink:href="TBSD_A_1808077_ILG0010_C.gif" content-type="color"/></td><td align="center">&#x02212;5.43</td><td align="center">Ser 144; Ser 144; Gly 143; Thr 26; Thr 26; Thr 26; His 41; Cys 145</td><td align="center">&#x02212;5.84</td><td align="center">Ser 294; Ser 294; Pro 344; Lys 290; His 235; His 235; Tyr 343; His 250; Thr 341</td></tr></tbody></table></table-wrap><sec id="S0003-S2001" disp-level="2"><title>Interaction of plant-derived compounds with active site of protein 3CL<sup>pro</sup></title><p>Bisdemethoxycurcumin and Demethoxycurcumin the analogues of curcumin, exhibited the docked score of &#x02212;7.3Kcal/mol and &#x02212;7.02Kcal/mol, and formed five hydrogen bonds with amino acid residues Lys-290, Gly-248, His-235, Thr-341, and Glu-340 and one hydrogen bond with His-163 amino acid residue, respectively (<xref ref-type="fig" rid="F0003">Figure 3</xref>). Scutellarin represented the binding affinity of &#x02212;7.13&#x02009;Kcal/mol was found to form two hydrogen bonds with amino acid residues Gly-143 and His-163, followed by flavonoid quercetin with binding energy of &#x02212;6.58Kcal/mol and hydrogen bonds formed with amino acids Asn-142, Gly-143, Ser-144, Leu-141, Cys-145, His-41, and Thr-26. Among all, four plant-derived compounds with binding affinity more than &#x02212;6.5Kcal/mol were myricetin (-6.15Kcal/mol), curcumin (-6.04Kcal/mol), bergapten (-5.98Kcal/mol) and isoflavone (-5.69Kcal/mol) with amino acids present in the docking pocket of 3CL<sup>pro</sup> shown in <xref rid="t0003" ref-type="table">Table 3</xref>. Furthermore, the anti-viral drugs remedesivir and ribavirin showed +196&#x02009;Kcal/mol and &#x02212;5.43&#x02009;Kcal/mol binding affinity, respectively.</p><fig id="F0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Binding interactions of eight plant-derived compounds <bold>(a-j)</bold> with the active site of SARS-CoV-2 3CL<sup>pro</sup> protein target site (PDB ID: 6LU7).</p></caption><graphic content-type="color" xlink:href="TBSD_A_1808077_F0003_C"/></fig></sec><sec id="S0003-S2002" disp-level="2"><title>Interaction of plant-derived compounds with active site of protein endoribonuclease</title><p>Compounds represented a similar kind of affinity with endoribonuclease as observed with 3CL<sup>pro</sup>. Based on binding affinities, three compounds were in common with both the protein targeted sites. Demethoxycurcumin with binding affinity of &#x02212;7.51Kcal/mol and formed five hydrogen bonds with Lys-290, Gly-248, His-235, Thr-341, and Glu-340 amino acid residue. Another compound scutellarin, with binding affinity of &#x02212;6.97Kcal/mol with Lys-290, His-250, Gly-248, and Glu-340 amino acids formed four hydrogen bonds within docking pocket followed by bisdemethoxycurcumin, binding affinity of &#x02212;6.56Kcal/mol and one hydrogen bond formation with Lys-290. The flavonoid group of myricetin and quercetin exhibited negligible difference in their binding energies &#x02212;6.52 and &#x02212;6.49&#x02009;Kcal/mol, but hydrogen bond formed with same amino acids residues in the pocket- Lys-290, His-235, His-250, and Glu-340. Bergapten (-5.89Kcal/mol) and isoflavone (-5.69Kcal/mol) also showed the minimum binding energy and formed hydrogen bonds. The anti-viral drugs remedesivir docked with &#x02212;7.7Kcal/mol with one hydrogen bond, whereas ribavirin binding energy (-5.84Kcal/mol) was found close to that of 3CL<sup>pro</sup> target site (<xref rid="t0003" ref-type="table">Table 3</xref>; <xref ref-type="fig" rid="F0004">Figure 4</xref>).</p><fig id="F0004" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Binding interactions of eight plant-derived compounds <bold>(a-j)</bold> with the active site of SARS-CoV-2 NSP15 endoribonuclease (PDB ID: 6VWW).</p></caption><graphic content-type="color" xlink:href="TBSD_A_1808077_F0004_C"/></fig><p>All the plant-derived compounds studied were analysed for their physicochemical properties and ADME to screen bioavailability via oral route. The eight compounds listed in <xref rid="t0004" ref-type="table">Table 4</xref> showed the five key criteria to qualify a compound to possess drug-like properties. The results explained that the plant-derived compounds studied would be more potent to be used as bioactive compounds as compared to the existing anti-viral drug remedesivir. All the compounds have molecular weight less than 500&#x02009;g/mol, lipophilicity (MlogP) value less than 5, hydrogen bond donor and acceptor are less than 5 and 10, respectively which corresponds to no violations of Lipinski&#x02019;s rule of five. Thus, it suggested that all of these studied compounds have the potential ability to work effectively as novel inhibitors.</p><table-wrap id="t0004" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Physicochemical analysis of potential inhibitors of 3CL<sup>pro</sup> and NSP15 endoribonuclease protein of SARS-CoV-2.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th colspan="2" align="left">Compounds</th><th align="center">Molecular formula</th><th align="center">ADME properties (Lipinki&#x02019;s rule of five)</th><th align="center">Values</th></tr></thead><tbody valign="top"><tr><td colspan="2">Demethoxycurcumin</td><td align="center">C<sub>20</sub>H<sub>18</sub>O<sub>5</sub></td><td align="left">Molecular weight (&#x0003c;500g/mol)<break/>LogP (&#x0003c;5)<break/>H-bond donor (&#x0003c;5)<break/>H-bond acceptor (&#x0003c;10)<break/>Violation</td><td align="center">338.4&#x02009;g/mol<break/>2.78<break/>2<break/>5<break/>0</td></tr><tr><td colspan="2">Curcumin</td><td align="center">C<sub>21</sub>H<sub>20</sub>O<sub>6</sub></td><td align="left">Molecular weight (&#x0003c;500g/mol)<break/>LogP (&#x0003c;5)<break/>H-bond donor (&#x0003c;5)<break/>H-bond acceptor (&#x0003c;10)<break/>Violation</td><td align="center">368.4&#x02009;g/mol<break/>3.27<break/>2<break/>6<break/>0</td></tr><tr><td colspan="2">Bisdemethoxycurcumin</td><td align="center">C<sub>19</sub>H<sub>16</sub>O<sub>4</sub></td><td align="left">Molecular weight (&#x0003c;500g/mol)<break/>LogP (&#x0003c;5)<break/>H-bond donor (&#x0003c;5)<break/>H-bond acceptor (&#x0003c;10)<break/>Violation</td><td align="center">308.3&#x02009;g/mol<break/>1.75<break/>2<break/>4<break/>0</td></tr><tr><td colspan="2">Quercetin</td><td align="center">C<sub>15</sub>H<sub>10</sub>O<sub>7</sub></td><td align="left">Molecular weight (&#x0003c;500g/mol)<break/>LogP (&#x0003c;5)<break/>H-bond donor (&#x0003c;5)<break/>H-bond acceptor (&#x0003c;10)<break/>Violation</td><td align="center">302.23&#x02009;g/mol<break/>1.63<break/>5<break/>7<break/>0</td></tr><tr><td colspan="2">Myricetin</td><td align="center">C<sub>15</sub>H<sub>10</sub>O<sub>8</sub></td><td align="left">Molecular weight (&#x0003c;500g/mol)<break/>LogP (&#x0003c;5)<break/>H-bond donor (&#x0003c;5)<break/>H-bond acceptor (&#x0003c;10)<break/>Violation</td><td align="center">318.23&#x02009;g/mol<break/>1.08<break/><bold>6</bold><break/>8<break/>1</td></tr><tr><td colspan="2">Bergapten</td><td align="center">C<sub>12</sub>H<sub>8</sub>O<sub>4</sub></td><td align="left">Molecular weight (&#x0003c;500g/mol)<break/>LogP (&#x0003c;5)<break/>H-bond donor (&#x0003c;5)<break/>H-bond acceptor (&#x0003c;10)<break/>Violation</td><td align="center">216.19&#x02009;g/mol<break/>2.29<break/>0<break/>4<break/>0</td></tr><tr><td colspan="2">Scutellarin</td><td align="center">C<sub>15</sub>H<sub>10</sub>O<sub>6</sub></td><td align="left">Molecular weight (&#x0003c;500g/mol)<break/>LogP (&#x0003c;5)<break/>H-bond donor (&#x0003c;5)<break/>H-bond acceptor (&#x0003c;10)<break/>Violation</td><td align="center">286.24&#x02009;g/mol<break/>2.08<break/>4<break/>6<break/>0</td></tr><tr><td colspan="2">Isoflavone</td><td align="center">C<sub>15</sub>H<sub>10</sub>O<sub>2</sub></td><td align="left">Molecular weight (&#x0003c;500g/mol)<break/>LogP (&#x0003c;5)<break/>H-bond donor (&#x0003c;5)<break/>H-bond acceptor (&#x0003c;10)<break/>Violation</td><td align="center">222.24&#x02009;g/mol<break/>2.51<break/>0<break/>2<break/>0</td></tr><tr><td colspan="2">Remdesivir</td><td align="center">C<sub>27</sub>H<sub>35</sub>N<sub>6</sub>O<sub>8</sub>P</td><td align="left">Molecular weight (&#x0003c;500g/mol)<break/>LogP (&#x0003c;5)<break/>H-bond donor (&#x0003c;5)<break/>H-bond acceptor (&#x0003c;10)<break/>Violation</td><td align="center"><bold>602.6&#x02009;g/mol</bold><break/>3.24<break/>4<break/><bold>13</bold><break/><bold>2</bold></td></tr><tr><td colspan="2">Ribavirin</td><td align="center">C<sub>8</sub>H<sub>12</sub>N<sub>4</sub>O<sub>5</sub></td><td align="left">Molecular weight (&#x0003c;500g/mol)<break/>LogP (&#x0003c;5)<break/>H-bond donor (&#x0003c;5)<break/>H-bond acceptor (&#x0003c;10)<break/>Violation</td><td align="center">244.2&#x02009;g/mol<break/>0.13<break/>4<break/>7<break/>0</td></tr></tbody></table></table-wrap></sec><sec id="S0003-S2003" disp-level="2"><title>Oral bioavailability and gastrointestinal (GI) absorption of interacted plant-derived compounds</title><p>The potential inhibitors of enzymes involved in replication and transcription of SARS-CoV-2 studied were analysed for their oral bioavailability as well as GI tract absorption parameters. The potent compounds extracted from various natural sources were listed in the <xref rid="t0001" ref-type="table">Table S1</xref>
<bold>(</bold>Supplementary material). Natural sources such as herbs, oils have many active compounds: Curcumin, Quercetin, Bergapten etc. which possess to have potential as anti-SARS-CoV-2 activity. The bioavailability of all the plant-based compounds is equal to 0.55 whereas remdesivir has lower bioavailability of 0.17. The absorption of the compounds by GI tract is high except for myricetin while the drugs have lower absorption rate.</p></sec><sec id="S0003-S2004" disp-level="2"><title>Molecular dynamics simulation</title><p>Molecular dynamics simulation has been preformed for 50&#x02009;ns simulation time for four systems, two from 3CL<sup>pro</sup> (receptor only and with selected dock ligand complex) and two from endoribonuclease (receptor and docked ligand complex). For each case, receptor only dynamics is used as a reference to assess the stability dynamics of the ligand bound complex. RMSD (<xref ref-type="fig" rid="F0005">Figure 5</xref>), RMSF (<xref ref-type="fig" rid="F0006">Figure 6</xref>) and SASA (<xref ref-type="fig" rid="F0007">Figure 7</xref>) is calculated to assess the time dependent evolution of the systems and stability dynamics. At the same time, Hydrogen-bond analysis has been done to understand the engagement of the docked ligand with the corresponding receptor (<xref ref-type="fig" rid="F0008">Figure 8</xref>).</p><fig id="F0005" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>RMSD plot of the 3CL<sup>pro</sup> system (above) and endoribonuclease system (below). For both cases, protein-ligand complex is showing better stability compared to the receptor alone.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1808077_F0005_C"/></fig><fig id="F0006" orientation="portrait" position="float"><label>Figure 6.</label><caption><p>RMSF analysis plot for 3CL<sup>pro</sup> system (above) and endoribonuclease system (below). As expected, except the binding site residues, nearly similar fluctuations are recorded for the both unbound and bound system. Binding site residues are less fluctuating in ligand complex compared to receptor only dynamics.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1808077_F0006_C"/></fig><fig id="F0007" orientation="portrait" position="float"><label>Figure 7.</label><caption><p>SASA plot for the 3CL<sup>pro</sup> system (above) and endoribonuclease system (below). For both systems, SASA are nearly consistent over time and reflects that after ligand binding receptor proteins do not undergo any large conformational change.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1808077_F0007_C"/></fig><fig id="F0008" orientation="portrait" position="float"><label>Figure 8.</label><caption><p>Hydrogen bond dynamics between Bisdemethoxycurcumin-3CL<sup>pro</sup> complex (above) and Demethoxycurcumin-endoribonuclease complex (below). This analysis shows that selected ligands engage with receptors with nearly two hydrogen bonds and do not deviate much from the initial structure.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1808077_F0008_C"/></fig></sec></sec><sec sec-type="discussion" id="S0004" disp-level="1"><title>Discussion</title><p>The rapidly spreading coronavirus disease SARS-CoV-2, also known as COVID-19, is declared as a pandemic outbreak by the WHO. It has affected the public as well as social health of more than 200 countries around the globe (<ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019">https://www.who.int/emergencies/diseases/novel-coronavirus-2019</ext-link>). Hence, it&#x02019;s the need of an hour that has demanded the scientific community from all over the world to collaborate and make an extraordinary effort for the rapid detection of an effective anti-COVID-19 drug.</p><p>The NSPs, endoribonuclease (NSP15) and main protease enzyme encoded by 3CL<sup>pro</sup> have been sequenced and their X-ray crystallography 3-D structures are available in PDB databank (Jin et&#x000a0;al., <xref rid="CIT0023" ref-type="bibr">2020</xref>; Kim et&#x000a0;al., <xref rid="CIT0027" ref-type="bibr">2020</xref>) . Each monomeric unit of endoribonuclease protein is comprised of &#x0223c;345 amino acids which are folded into three domains: N-terminal, middle and NendoU C-terminal catalytic domain. The NendoU C-terminal catalytic domain reported to possess two &#x003b2;-sheets in antiparallel direction (Sinha et&#x000a0;al., <xref rid="CIT0049" ref-type="bibr">2020</xref>). This protein is required by the virus as it takes part in various viral mechanisms including the formation of the replicase and transcriptase complex (RTC) (Deng et&#x000a0;al., <xref rid="CIT0009" ref-type="bibr">2017</xref>). Also, in innate immune response, therefore NSP15 considered to be essential for biological progression of coronavirus. Study has reported that the main active sites of Nsp15 protein, conserved among SARS-CoV-2, SARS-CoV and MERS-CoV are located in a shallow groove between the two &#x003b2;-sheets that comprise six amino acids (His235, His250, Lys290, Thr341, Tyr343, and Ser294) (Sinha et&#x000a0;al., <xref rid="CIT0049" ref-type="bibr">2020</xref>).</p><p>The main protease, 3CL<sup>pro</sup> protein is a homodimer with Cys-His catalytic dyad on the active site which is responsible for the protease activity and hence inhibiting the catalytic site present in enzyme would lead to the inhibition of activity of the protein(Islam et&#x000a0;al., <xref rid="CIT0022" ref-type="bibr">2020</xref>; Lobo-Galo et&#x000a0;al., <xref rid="CIT0034" ref-type="bibr">2020</xref>). The secondary structures of 3CL<sup>pro</sup>, has three domins: Domains I and II which have an antiparallel &#x003b2;-barrel structure and Domain III contains five &#x003b1;-helices arranged into a largely antiparallel globular cluster, and is connected to domain II by means of a long loop region. These features are similar to those of other M<sub>pro</sub> reported previously (Ren et&#x000a0;al., <xref rid="CIT0043" ref-type="bibr">2013</xref>; Wang et&#x000a0;al., <xref rid="CIT0054" ref-type="bibr">2016</xref>; Xue et&#x000a0;al., <xref rid="CIT0057" ref-type="bibr">2008</xref>).</p><p>At present, there are no approved medications from different drug administrations around the world for the treatment of novel coronavirus (SARS-CoV-2). Hence, the primary focus has been on clinical management which includes the prevention of infection, control measures and intensive supportive care. Recently, anti-malarial drugs like chloroquine, hydroxychloroquine have given positive results in the cell culture systems but has to proceed for the clinical trials to be established as an effective drug (Enmozhi et&#x000a0;al., <xref rid="CIT0014" ref-type="bibr">2020</xref>). Several other anti-viral drugs such as remdesivir, ribavirin used in hepatitis C infection and Ebola, and many other vaccines are under rapid study to be used against coronavirus infection.</p><p>An anti-viral activity of curcumin and its analogues demethoxycurcumin and bisdemethoxycurcumin was reported against several different viruses including hepatitis viruses, influenza viruses and emerging arboviruses like the Zika virus (ZIKV) (Mounce et&#x000a0;al., <xref rid="CIT0037" ref-type="bibr">2017</xref>) or chikungunya virus (CHIKV) (von Rhein et&#x000a0;al., <xref rid="CIT0053" ref-type="bibr">2016</xref>). These analogues have described role as a metabolite, an anti-neoplastic agent and an anti-inflammatory agent in PubChem databank. They possess much greater chemical stability at physiological pH. Scutellarin is a glycosyloxyflavone, a glucosiduronic acid, a trihydroxyflavone and a monosaccharide derivative. (Cheng et&#x000a0;al., <xref rid="CIT0008" ref-type="bibr">2013</xref>) observed that it could inactivate porcine reproductive and respiratory syndrome virus (PRRSV) and restrict the early stage of PRRSV replication under <italic>in&#x000a0;vitro</italic> conditions. Similarly, Zhang et&#x000a0;al.(2005) demonstrated that it possessed anti-HIV-1 activity by inhibiting HIV-1 reverse transcriptase activity, HIV-1 particle attachment and cell fusion (Cheng et&#x000a0;al., <xref rid="CIT0008" ref-type="bibr">2013</xref>; Sun et&#x000a0;al., <xref rid="CIT0050" ref-type="bibr">2015</xref>). Quercetin is a polyphenol, known as flavonoids, its various pharmacological activities described in the literature such as anti-inflammatory, anti-oxidant, anti-enzymatic activities. (Polansky &#x00026; Lori, <xref rid="CIT0041" ref-type="bibr">2020</xref>) concluded that quercetin and its derivatives were reported to inhibit the SARS and MERS virus replication via protease inhibition (Cheng et&#x000a0;al., <xref rid="CIT0008" ref-type="bibr">2013</xref>). Myricetin is structurally related to several well-known phenolic compounds namely quercetin, morin, kaempferol and fisetin. Myricetin demonstrated antiviral activity as a strong inhibitor of reverse transcriptase against Rauscher murine leukemia virus (RLV) and human immunodeficiency virus (HIV). Some studies reported that bergapten exhibited potent anti-HIV activity via inhibition of HIV-1 replication with therapeutic index value greater than 5.0 (Shikishima et&#x000a0;al., <xref rid="CIT0048" ref-type="bibr">2001</xref>). According to literature, it has been reported that 5,7,3&#x02032;,4&#x02032;-tetrahydroxy-2&#x02032;-(3,3-dimethylallyl) isoflavone used as an anti-leishmanial agent (Salem &#x00026; Werbovetz, <xref rid="CIT0046" ref-type="bibr">2006</xref>), and it is also described in traditional Chinese medicine records (Zhou et&#x000a0;al., <xref rid="CIT0059" ref-type="bibr">2011</xref>).</p><p>The preliminary screening of potential molecules having anti-viral activity via computational approach would help in providing the fast selection of promising compounds towards the development of therapeutics against SARS- CoV-2. To elucidate the binding affinity of plant-derived compounds with known properties of anti-viral, were docked against two NSPs of COVID-19 using AutoDock4 software (<xref rid="t0002" ref-type="table">Table 2</xref>; <xref ref-type="fig" rid="F0001">Figure 1</xref> and 2). The binding scores from the docking study revealed the affinity of a specific ligand and strength by which a compound interacts with and binds to the pocket of a target protein. Docking results were successful with least binding scores and presence of significant hydrogen bonding with demethoxycurcumin, bisdemethoxycurcumin and a flavone scutellarin. Compounds having binding affinity of &#x02212;6.5&#x02009;Kcal/mol or less are considered to be a good inhibitor of enzymatic activities (Shah et&#x000a0;al., <xref rid="CIT0047" ref-type="bibr">2020</xref>). In the present study, five plant-derived compounds demonstrated binding affinity more negative to &#x02212;6.5Kcal/mol with 3CL<sup>pro</sup>, whereas with NSP15 endoribonuclease, five different plant-derived compounds exhibited the same results. These compounds could be potent drugs for inhibition of two essential viral proteins and thus inhibiting the viral replication in the infected cells. Additionally, the <italic>in-silico</italic> experiment represented the inability of remdesivir to bind with 3CL<sup>pro</sup>, as binding affinity of remdesivir was +196&#x02009;Kcal/mol, which showed instability. In contrast, Remdesivir contributes &#x02212;6.58&#x02009;kcal/mol to the binding free energy at the electrostatic S1 subsite of protease protein (Khan et&#x000a0;al., <xref rid="CIT0026" ref-type="bibr">2020</xref>).</p><p>Further, the physicochemical properties of these compounds were studied by ADME-Tox following the Lipinski&#x02019;s rule of five for evaluating drug likeness. Lipinski&#x02019;s rule determines the molecular properties which are important for a drug&#x02019;s pharmacokinetics in the human body such as absorption, distribution, metabolism, and excretion (ADME). Lipinski&#x02019;s rule of five criteria for an ideal drug are (i) a molecular mass less than 500 Daltons (ii) no more than 5 hydrogen bond donors, (iii) no more than 10 hydrogen bond acceptors, (iv) an octanol&#x02013;water partition coefficient log P not greater than 5. Three or more than 3 violations of Lipinski&#x02019;s rule do not fit into the criteria of drug likeliness via oral route administration (Benet et&#x000a0;al., <xref rid="CIT0003" ref-type="bibr">2016</xref>). ADME-Tox studies of docked eight plant-derived compounds showed that all the compounds had virtual hits and were successful at passing through these ADME-Tox test filters, stating that they could be potential drugs which can be easily administered orally (<xref rid="t0004" ref-type="table">Table 4</xref>).</p><p>The other crucial experiments like bioavailability and GI absorptions are of detecting the low bioavailability is a major concern for drug design, as it may lead to failure of a novel drug in the clinical trials, in spite of the fact that the compounds have high efficacy in <italic>in-vitro</italic> and/or <italic>in-vivo</italic> tests (Gyebi et&#x000a0;al., <xref rid="CIT0019" ref-type="bibr">2020</xref>). Therefore, oral bioavailability of a compound is essential to be taken into account when predicting the compound as a drug candidate. The compounds in the present study exhibited bioavailability of 0.55 with low as well as high GI absorption. The absorption into GI was found to be at a high rate in all compounds except that of Myricetin.</p><p>Protein flexibility plays an essential role in the inhibitor designing process (Teague, <xref rid="CIT0051" ref-type="bibr">2003</xref>) and as molecular docking has been performed using the single structure, molecular dynamic simulation can provide an in-depth understanding of the protein-ligand interaction information. 3CL<sup>pro</sup> and endoribonuclease proteins, along with selected compounds, were used for MDS analysis, which suggests that the ligand-bound receptor adopt stability over the receptor only dynamics (<xref ref-type="fig" rid="F0005">Figure 5</xref> and <xref ref-type="fig" rid="F0007">7</xref>). H-bond based interaction analysis suggests that both docked compounds with respective proteins utilize the available binding interactions and maintain these interactions throughout the simulation time (<xref ref-type="fig" rid="F0008">Figure 8</xref>). Apart from the receptor-based interaction, docked ligand also formed on average two H-bonds with the nearly water molecules which additionally provide the stability to the docked ligand (Supplementary material <xref ref-type="fig" rid="F0003">Figure S3</xref>).</p></sec><sec sec-type="conclusions" id="S0005" disp-level="1"><title>Conclusion</title><p>In the current scenario, there is an urgent requirement of the potential treatment of SARS-CoV-2 infection. Compounds extracted from natural sources might be a source in the development of new potent drugs which can improve the novel coronavirus treatment. Various plant-derived compounds have been reported for their anti-viral activity, may found to be effective against SARS-CoV-2. The bioinformatics approach could be a very useful and efficient tool to identify potent inhibitors against the specific targets of novel coronavirus. The docking study concluded that plant-derived compounds (Demethoxycurcumin, Bisdemethoxycurcumin, Scutellarin, Quercetin and Myricetin) exhibited potential drug candidates against two enzymes, main protease (3CL<sup>pro</sup>) and endoribonuclease (NSP15) proteins of SARS-CoV-2. Also, molecular dynamics and simulations of two best docked protein-ligand structures revealed the dynamics information of their stability in the biological system. Instability of these two enzyme activities would lead to inhibition of viral replication, which in response would restrict the infection in the host cell.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SM7578"><caption><title>Supplemental Material</title></caption><media xlink:href="TBSD_A_1808077_SM7578.jpg"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM2135"><caption><title>Supplementary_document......docx</title></caption><media xlink:href="TBSD_A_1808077_SM2135.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><title>Acknowledgements</title><p>The authors would like to thank Amity University Uttar Pradesh, India for providing facilities to carry out this work. The authors also would like to thank the researchers who generated and shared the sequencing and protein data of main protease (3CL<sup>pro</sup>) and endoribonuclease (NSP15) proteins of SARS-CoV-2 in Protein Data Bank website (<ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/">https://www.rcsb.org/</ext-link>). The authors would like to acknowledge Ms. Sapna Ratnakar, Ph.D. Scholar, School of Life Sciences, JNU for providing her support to carry out MDS. P.K. would like to thank DBT Project for supporting the research work and also thank Dr. Debabsisa Mohanty for providing the NII computational facility to carry out the simulation analysis.</p></ack><sec id="S0006" disp-level="1" sec-type="COI-statement"><title>Disclosure statement</title><p>The authors declare no potential conflicts of interest to disclose.</p></sec><sec id="S0007" disp-level="1"><title>Authors contributions</title><p>All authors conceived, conducted and analyzed the results of experiment(s) equally. L.G. performed docking studies, manuscript editing; A.S. and S.G. drafted manuscript, performed ADMET studies; A.K.Y. manuscript editing, result analysis and P.K. performed molecular dynamics and simulations.</p></sec><notes><sec sec-type="correction-statement"><title>Correction Statement</title><p>This article has been republished with minor changes. These changes do not impact the academic content of the article.</p></sec></notes><ref-list><title>References</title><ref id="CIT0001"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akula</surname><given-names>S. M.</given-names></name>, <name name-style="western"><surname>Hurley</surname><given-names>D. J.</given-names></name>, <name name-style="western"><surname>Wixon</surname><given-names>R. L.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name>, &#x00026; <name name-style="western"><surname>Chase</surname><given-names>C. C. L.</given-names></name></person-group> (<year>2002</year>). <article-title>Effect of genistein on replication of bovine herpesvirus type 1</article-title>. <source><italic toggle="yes">American Journal of Veterinary Research</italic></source>, (<issue>8</issue>), <fpage>1124</fpage>&#x02013;<lpage>1128</lpage>. <pub-id pub-id-type="doi">10.2460/ajvr.2002.63.1124</pub-id><pub-id pub-id-type="pmid">12171165</pub-id></mixed-citation></ref><ref id="CIT0002"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baikerikar</surname><given-names>S.</given-names></name></person-group> (<year>2017</year>). <article-title>Curcumin and natural derivatives inhibit Ebola viral proteins: An In silico approach</article-title>. <source><italic toggle="yes">Pharmacognosy Research</italic></source>, (<issue>5</issue>), <fpage>15</fpage>
<pub-id pub-id-type="doi">10.4103/pr.pr_30_17</pub-id></mixed-citation></ref><ref id="CIT0003"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benet</surname><given-names>L. Z.</given-names></name>, <name name-style="western"><surname>Hosey</surname><given-names>C. M.</given-names></name>, <name name-style="western"><surname>Ursu</surname><given-names>O.</given-names></name>, &#x00026; <name name-style="western"><surname>Oprea</surname><given-names>T. I.</given-names></name></person-group> (<year>2016</year>). <article-title>BDDCS, the Rule of 5 and drugability</article-title>. <source><italic toggle="yes">Advanced Drug Delivery Reviews</italic></source>, , <fpage>89</fpage>&#x02013;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2016.05.007</pub-id><pub-id pub-id-type="pmid">27182629</pub-id></mixed-citation></ref><ref id="CIT0004"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boopathi</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Poma</surname><given-names>A. B.</given-names></name>, &#x00026; <name name-style="western"><surname>Kolandaivel</surname><given-names>P.</given-names></name></person-group> (<year>2020</year>). <article-title>Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure and Dynamics</italic></source>, ,<fpage>1</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1758788</pub-id></mixed-citation></ref><ref id="CIT0005"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>J. F. W.</given-names></name>, <name name-style="western"><surname>Kok</surname><given-names>K. H.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Chu</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>To</surname><given-names>K. K. W.</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>S.</given-names></name>, &#x00026; <name name-style="western"><surname>Yuen</surname><given-names>K. Y.</given-names></name></person-group> (<year>2020</year>). <article-title>Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan</article-title>. <source><italic toggle="yes">Emerging Microbes &#x00026; Infections</italic></source>, (<issue>1</issue>), <fpage>221</fpage>&#x02013;<lpage>236</lpage>. <pub-id pub-id-type="doi">10.1080/22221751.2020.1719902</pub-id><pub-id pub-id-type="pmid">31987001</pub-id></mixed-citation></ref><ref id="CIT0006"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>J. F.-W.</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Kok</surname><given-names>K.-H.</given-names></name>, <name name-style="western"><surname>To</surname><given-names>K. K.-W.</given-names></name>, <name name-style="western"><surname>Chu</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Xing</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Yip</surname><given-names>C. C.-Y.</given-names></name>, <name name-style="western"><surname>Poon</surname><given-names>R. W.-S.</given-names></name>, <name name-style="western"><surname>Tsoi</surname><given-names>H.-W.</given-names></name>, <name name-style="western"><surname>Lo</surname><given-names>S. K.-F.</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>K.-H.</given-names></name>, <name name-style="western"><surname>Poon</surname><given-names>V. K.-M.</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>W.-M.</given-names></name>, <name name-style="western"><surname>Ip</surname><given-names>J. D.</given-names></name>, <name name-style="western"><surname>Cai</surname><given-names>J.-P.</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>V. C.-C.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Hui</surname><given-names>C. K.-M.</given-names></name>, &#x02026; <name name-style="western"><surname>Yuen</surname><given-names>K.-Y.</given-names></name></person-group> (<year>2020</year>). <article-title>A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster</article-title>. <source><italic toggle="yes">The Lancet</italic></source>, (<issue>10223</issue>), <fpage>514</fpage>&#x02013;<lpage>523</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30154-9</pub-id></mixed-citation></ref><ref id="CIT0007"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chandel</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Raj</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Rathi</surname><given-names>B.</given-names></name>, &#x00026; <name name-style="western"><surname>Kumar</surname><given-names>D.</given-names></name></person-group> (<year>2020</year>). <article-title>In silico identification of potent COVID-19 main protease inhibitors from FDA approved antiviral compounds and active phytochemicals through molecular docking: A drug repurposing approach</article-title>. <italic>7</italic>(3), 1-9.<pub-id pub-id-type="doi">10.20944/preprints202003.0349.v1</pub-id></mixed-citation></ref><ref id="CIT0008"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Niu</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Bai</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>He</surname><given-names>J.</given-names></name>, &#x00026; <name name-style="western"><surname>Li</surname><given-names>H.</given-names></name></person-group> (<year>2013</year>). <article-title>In vitro screening for compounds derived from traditional Chinese medicines with antiviral activities against porcine reproductive and respiratory syndrome virus</article-title>. <source><italic toggle="yes">Journal of Microbiology and Biotechnology</italic></source>, (<issue>8</issue>), <fpage>1076</fpage>&#x02013;<lpage>1083</lpage>. <pub-id pub-id-type="doi">10.4014/jmb.1303.03074</pub-id><pub-id pub-id-type="pmid">23727804</pub-id></mixed-citation></ref><ref id="CIT0009"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Hackbart</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Mettelman</surname><given-names>R. C.</given-names></name>, <name name-style="western"><surname>O'Brien</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Mielech</surname><given-names>A. M.</given-names></name>, <name name-style="western"><surname>Yi</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Kao</surname><given-names>C. C.</given-names></name>, &#x00026; <name name-style="western"><surname>Baker</surname><given-names>S. C.</given-names></name></person-group> (<year>2017</year>). <article-title>Coronavirus nonstructural protein 15 mediates evasion of dsRNA sensors and limits apoptosis in macrophages</article-title>. <source><italic toggle="yes">Proceedings of the National Academy of Sciences of the United States of America</italic></source>, (<issue>21</issue>), <fpage>E4251</fpage>&#x02013;<lpage>E4260</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1618310114</pub-id><pub-id pub-id-type="pmid">28484023</pub-id></mixed-citation></ref><ref id="CIT0010"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhama</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Tiwari</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Sircar</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Bhat</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Malik</surname><given-names>Y. S.</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>K. P.</given-names></name>, <name name-style="western"><surname>Chaicumpa</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Bonilla-Aldana</surname><given-names>D. K.</given-names></name>, &#x00026; <name name-style="western"><surname>Rodriguez-Morales</surname><given-names>A. J.</given-names></name></person-group> (<year>2020</year>). <article-title>Coronavirus Disease 2019&#x02013;COVID-19</article-title>. <source><italic toggle="yes">Clinical Microbiology Reviews</italic></source>, (<issue>4</issue>), e00028&#x02013;20. <pub-id pub-id-type="doi">10.1128/CMR.00028-20</pub-id></mixed-citation></ref><ref id="CIT0011"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Dorm&#x000e1;n</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Flachner</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Hajd&#x000fa;</surname><given-names>I.</given-names></name>, &#x00026; <name name-style="western"><surname>Andr&#x000e1;s</surname><given-names>C. D.</given-names></name></person-group> (<year>2016</year>). <chapter-title>Target Identification and Polypharmacology of Nutraceuticals</chapter-title> In <source><italic toggle="yes">Nutraceuticals</italic></source> (pp. <fpage>263</fpage>&#x02013;<lpage>286</lpage>). <publisher-name>Elsevier</publisher-name>
<pub-id pub-id-type="doi">10.1016/B978-0-12-802147-7.00021-8</pub-id></mixed-citation></ref><ref id="CIT0012"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elfiky</surname><given-names>A. A.</given-names></name></person-group> (<year>2020</year>). <article-title>Natural products may interfere with SARS-CoV-2 attachment to the host cell</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure and Dynamics</italic></source>, , <fpage>1</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1761881</pub-id></mixed-citation></ref><ref id="CIT0013"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elmezayen</surname><given-names>A. D.</given-names></name>, <name name-style="western"><surname>Al-Obaidi</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>&#x0015e;ahin</surname><given-names>A. T.</given-names></name>, &#x00026; <name name-style="western"><surname>Yelek&#x000e7;i</surname><given-names>K.</given-names></name></person-group> (<year>2020</year>). <article-title>Drug repurposing for coronavirus (COVID-19): In silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure and Dynamics</italic></source>, , <fpage>1</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1758791</pub-id></mixed-citation></ref><ref id="CIT0014"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enmozhi</surname><given-names>S. K.</given-names></name>, <name name-style="western"><surname>Raja</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Sebastine</surname><given-names>I.</given-names></name>, &#x00026; <name name-style="western"><surname>Joseph</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: An in silico approach</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure and Dynamics</italic></source>, , <fpage>1</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1760136</pub-id></mixed-citation></ref><ref id="CIT0015"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Essmann</surname><given-names>U.</given-names></name>, <name name-style="western"><surname>Perera</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Berkowitz</surname><given-names>M. L.</given-names></name>, <name name-style="western"><surname>Darden</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name>, &#x00026; <name name-style="western"><surname>Pedersen</surname><given-names>L. G.</given-names></name></person-group> (<year>1995</year>). <article-title>A smooth particle mesh Ewald method</article-title>. <source><italic toggle="yes">The Journal of Chemical Physics</italic></source>, (<issue>19</issue>), <fpage>8577</fpage>&#x02013;<lpage>8593</lpage>. <pub-id pub-id-type="doi">10.1063/1.470117</pub-id></mixed-citation></ref><ref id="CIT0016"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gajula</surname><given-names>M. P.</given-names></name>, <name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name>, &#x00026; <name name-style="western"><surname>Ijaq</surname><given-names>J.</given-names></name></person-group> (<year>2016</year>). <article-title>Protocol for molecular dynamics simulations of proteins</article-title>. <source>Bio-Protocol</source>, (<issue>23</issue>), <fpage>e2051</fpage>&#x02013;<lpage>e2051</lpage>. <pub-id pub-id-type="doi">10.21769/BioProtoc.2051</pub-id></mixed-citation></ref><ref id="CIT0017"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geourjon</surname><given-names>C.</given-names></name>, &#x00026; <name name-style="western"><surname>Del&#x000e9;age</surname><given-names>G.</given-names></name></person-group> (<year>1995</year>). <article-title>SOPMA: Significant improvements in protein secondary structure prediction by consensus prediction from multiple alignments</article-title>. <source><italic toggle="yes">Computer Applications in the Biosciences: Cabios</italic></source>, (<issue>6</issue>), <fpage>681</fpage>&#x02013;<lpage>684</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/11.6.681</pub-id><pub-id pub-id-type="pmid">8808585</pub-id></mixed-citation></ref><ref id="CIT0018"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Y. R.</given-names></name>, <name name-style="western"><surname>Cao</surname><given-names>Q. D.</given-names></name>, <name name-style="western"><surname>Hong</surname><given-names>Z. S.</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>Y. Y.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>S. D.</given-names></name>, <name name-style="western"><surname>Jin</surname><given-names>H. J.</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>K. S.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>D. Y.</given-names></name>, &#x00026; <name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></name></person-group> (<year>2020</year>). <article-title>The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status</article-title>. <source><italic toggle="yes">Military Medical Research</italic></source>, (<issue>1</issue>), <fpage>11</fpage>
<pub-id pub-id-type="doi">10.1186/s40779-020-00240-0</pub-id><pub-id pub-id-type="pmid">32169119</pub-id></mixed-citation></ref><ref id="CIT0019"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gyebi</surname><given-names>G. A.</given-names></name>, <name name-style="western"><surname>Ogunro</surname><given-names>O. B.</given-names></name>, <name name-style="western"><surname>Adegunloye</surname><given-names>A. P.</given-names></name>, <name name-style="western"><surname>Ogunyemi</surname><given-names>O. M.</given-names></name>, &#x00026; <name name-style="western"><surname>Afolabi</surname><given-names>S. O.</given-names></name></person-group> (<year>2020</year>). <article-title>Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CLpro): An in silico screening of Alkaloids and Terpenoids from African medicinal plants</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure and Dynamics</italic></source>, , <fpage>1</fpage>&#x02013;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1764868</pub-id></mixed-citation></ref><ref id="CIT0020"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hackbart</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Deng</surname><given-names>X.</given-names></name>, &#x00026; <name name-style="western"><surname>Baker</surname><given-names>S. C.</given-names></name></person-group> (<year>2020</year>). <article-title>Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors</article-title>. <source><italic toggle="yes">Proceedings of the National Academy of Sciences of the United States of America</italic></source>, (<issue>14</issue>), <fpage>8094</fpage>&#x02013;<lpage>8103</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1921485117</pub-id><pub-id pub-id-type="pmid">32198201</pub-id></mixed-citation></ref><ref id="CIT0021"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoda</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Gupta</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Agarwal</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Raj</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Vermani</surname><given-names>M.</given-names></name>, &#x00026; <name name-style="western"><surname>Vijayaraghavan</surname><given-names>P.</given-names></name></person-group> (<year>2019</year>). <article-title>Inhibition of aspergillus fumigatus biofilm and cytotoxicity study of natural compound cis-9-hexadecenal</article-title>. <source><italic toggle="yes">Journal of Pure and Applied Microbiology</italic></source>, (<issue>2</issue>), <fpage>1207</fpage>&#x02013;<lpage>1216</lpage>. <pub-id pub-id-type="doi">10.22207/JPAM.13.2.61</pub-id></mixed-citation></ref><ref id="CIT0022"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Islam</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Parves</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Paul</surname><given-names>A. S.</given-names></name>, <name name-style="western"><surname>Uddin</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Rahman</surname><given-names>M. S.</given-names></name>, <name name-style="western"><surname>Mamun</surname><given-names>A. A.</given-names></name>, <name name-style="western"><surname>Hossain</surname><given-names>M. N.</given-names></name>, <name name-style="western"><surname>Ali</surname><given-names>M. A.</given-names></name>, &#x00026; <name name-style="western"><surname>Halim</surname><given-names>M. A.</given-names></name></person-group> (<year>2020</year>). <article-title>A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure and Dynamics</italic></source>, , <fpage>1</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1761883</pub-id></mixed-citation></ref><ref id="CIT0023"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Du</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Peng</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Duan</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>You</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name>, &#x02026; <name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name></person-group> (<year>2020</year>). <article-title>Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors</article-title>. <source>Nature</source>, (<issue>7811</issue>), <fpage>289</fpage>&#x02013;<lpage>293</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2223-y</pub-id><pub-id pub-id-type="pmid">32272481</pub-id></mixed-citation></ref><ref id="CIT0024"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jorgensen</surname><given-names>W. L.</given-names></name>, <name name-style="western"><surname>Chandrasekhar</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Madura</surname><given-names>J. D.</given-names></name>, <name name-style="western"><surname>Impey</surname><given-names>R. W.</given-names></name>, &#x00026; <name name-style="western"><surname>Klein</surname><given-names>M. L.</given-names></name></person-group> (<year>1983</year>). <article-title>Comparison of simple potential functions for simulating liquid water</article-title>. <source><italic toggle="yes">The Journal of Chemical Physics</italic></source>, (<issue>2</issue>), <fpage>926</fpage>&#x02013;<lpage>935</lpage>. <pub-id pub-id-type="doi">10.1063/1.445869</pub-id></mixed-citation></ref><ref id="CIT0025"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joshi</surname><given-names>R. S.</given-names></name>, <name name-style="western"><surname>Jagdale</surname><given-names>S. S.</given-names></name>, <name name-style="western"><surname>Bansode</surname><given-names>S. B.</given-names></name>, <name name-style="western"><surname>Shankar</surname><given-names>S. S.</given-names></name>, <name name-style="western"><surname>Tellis</surname><given-names>M. B.</given-names></name>, <name name-style="western"><surname>Pandya</surname><given-names>V. K.</given-names></name>, <name name-style="western"><surname>Chugh</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Giri</surname><given-names>A. P.</given-names></name>, &#x00026; <name name-style="western"><surname>Kulkarni</surname><given-names>M. J.</given-names></name></person-group> (<year>2020</year>). <article-title>Discovery of potential multi-target-directed ligands by targeting host-specific SARS-CoV-2 structurally conserved main protease</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure and Dynamics</italic></source>, , <fpage>1</fpage>&#x02013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1760137</pub-id></mixed-citation></ref><ref id="CIT0026"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>S. A.</given-names></name>, <name name-style="western"><surname>Zia</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Ashraf</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Uddin</surname><given-names>R.</given-names></name>, &#x00026; <name name-style="western"><surname>Ul-Haq</surname><given-names>Z.</given-names></name></person-group> (<year>2020</year>). <article-title>Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure and Dynamics</italic></source>, , <fpage>1</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1751298</pub-id></mixed-citation></ref><ref id="CIT0027"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Jedrzejczak</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Maltseva</surname><given-names>N. I.</given-names></name>, <name name-style="western"><surname>Wilamowski</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Endres</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Godzik</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Michalska</surname><given-names>K.</given-names></name>, &#x00026; <name name-style="western"><surname>Joachimiak</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2</article-title>. <source><italic toggle="yes">Protein Science</italic></source>, (<issue>7</issue>), <fpage>1596</fpage>&#x02013;<lpage>1605</lpage>. <pub-id pub-id-type="doi">10.1002/pro.3873</pub-id><pub-id pub-id-type="pmid">32304108</pub-id></mixed-citation></ref><ref id="CIT0028"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Jedrzejczak</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Maltseva</surname><given-names>N. I.</given-names></name>, <name name-style="western"><surname>Wilamowski</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Endres</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Godzik</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Michalska</surname><given-names>K.</given-names></name>, &#x00026; <name name-style="western"><surname>Joachimiak</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2</article-title><source>. <italic toggle="yes">Protein Sci</italic></source>, (<issue>7</issue>), <fpage>1596</fpage>&#x02013;<lpage>1605</lpage>. <pub-id pub-id-type="doi">10.1002/pro.3873</pub-id><pub-id pub-id-type="pmid">32304108</pub-id></mixed-citation></ref><ref id="CIT0029"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kitazato</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>, &#x00026; <name name-style="western"><surname>Kobayashi</surname><given-names>N.</given-names></name></person-group> (<year>2007</year>). <article-title>Viral infectious disease and natural products with antiviral activity</article-title>. <source><italic toggle="yes">Drug Discoveries &#x00026; Therapeutics</italic></source>, (<issue>1</issue>), <fpage>14</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">22504360</pub-id></mixed-citation></ref><ref id="CIT0030"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kutluay</surname><given-names>S. B.</given-names></name>, <name name-style="western"><surname>Doroghazi</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Roemer</surname><given-names>M. E.</given-names></name>, &#x00026; <name name-style="western"><surname>Triezenberg</surname><given-names>S. J.</given-names></name></person-group> (<year>2008</year>). <article-title>Curcumin inhibits herpes simplex virus immediate-early gene expression by a mechanism independent of p300/CBP histone acetyltransferase activity</article-title>. <source>Virology</source>, (<issue>2</issue>), <fpage>239</fpage>&#x02013;<lpage>247</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2007.11.028</pub-id></mixed-citation></ref><ref id="CIT0031"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>K. P.</given-names></name>, <name name-style="western"><surname>Ng</surname><given-names>L. F. P.</given-names></name>, &#x00026; <name name-style="western"><surname>Liu</surname><given-names>D. X.</given-names></name></person-group> (<year>2000</year>). <article-title>Identification of a novel cleavage activity of the first papain-like proteinase domain encoded by open reading frame 1a of the coronavirus avian infectious bronchitis virus and characterization of the cleavage products</article-title>. <source><italic toggle="yes">Journal of Virology</italic></source>, (<issue>4</issue>), <fpage>1674</fpage>&#x02013;<lpage>1685</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.74.4.1674-1685.2000</pub-id><pub-id pub-id-type="pmid">10644337</pub-id></mixed-citation></ref><ref id="CIT0032"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Garner</surname><given-names>L. V.</given-names></name>, <name name-style="western"><surname>Watkins</surname><given-names>S. P.</given-names></name>, <name name-style="western"><surname>Carter</surname><given-names>L. J.</given-names></name>, <name name-style="western"><surname>Smoot</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Gregg</surname><given-names>A. C.</given-names></name>, <name name-style="western"><surname>Daniels</surname><given-names>A. D.</given-names></name>, <name name-style="western"><surname>Jervey</surname><given-names>S.</given-names></name>, &#x00026; <name name-style="western"><surname>Albaiu</surname><given-names>D.</given-names></name></person-group> (<year>2020</year>). <article-title>Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases</article-title>. <source><italic toggle="yes">ACS Central Science</italic></source>, (<issue>3</issue>), <fpage>315</fpage>&#x02013;<lpage>331</lpage>. <pub-id pub-id-type="doi">10.1021/acscentsci.0c00272</pub-id><pub-id pub-id-type="pmid">32226821</pub-id></mixed-citation></ref><ref id="CIT0033"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Fang</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Fang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Hong</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Peng</surname><given-names>G.</given-names></name>, &#x00026; <name name-style="western"><surname>Xiao</surname><given-names>S.</given-names></name></person-group> (<year>2019</year>). <article-title>Porcine deltacoronavirus nsp15 antagonizes interferon-&#x003b2; production independently of its endoribonuclease activity</article-title>. <source><italic toggle="yes">Molecular Immunology</italic></source>, , <fpage>100</fpage>&#x02013;<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1016/j.molimm.2019.07.003</pub-id><pub-id pub-id-type="pmid">31351410</pub-id></mixed-citation></ref><ref id="CIT0034"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lobo-Galo</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Terrazas-L&#x000f3;pez</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Mart&#x000ed;nez-Mart&#x000ed;nez</surname><given-names>A.</given-names></name>, &#x00026; <name name-style="western"><surname>D&#x000ed;az-S&#x000e1;nchez</surname><given-names>&#x000c1;. G.</given-names></name></person-group> (<year>2020</year>). <article-title>FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure and Dynamics</italic></source>,&#x000a0;<italic>38,</italic>
<fpage>1</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1764393</pub-id></mixed-citation></ref><ref id="CIT0035"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maier</surname><given-names>J. A.</given-names></name>, <name name-style="western"><surname>Martinez</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Kasavajhala</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Wickstrom</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Hauser</surname><given-names>K. E.</given-names></name>, &#x00026; <name name-style="western"><surname>Simmerling</surname><given-names>C.</given-names></name></person-group> (<year>2015</year>). <article-title>ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB</article-title>. <source><italic toggle="yes">Journal of Chemical Theory and Computation</italic></source>, (<issue>8</issue>), <fpage>3696</fpage>&#x02013;<lpage>3713</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jctc.5b00255</pub-id><pub-id pub-id-type="pmid">26574453</pub-id></mixed-citation></ref><ref id="CIT0036"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morris</surname><given-names>G. M.</given-names></name>, <name name-style="western"><surname>Huey</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Lindstrom</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Sanner</surname><given-names>M. F.</given-names></name>, <name name-style="western"><surname>Belew</surname><given-names>R. K.</given-names></name>, <name name-style="western"><surname>Goodsell</surname><given-names>D. S.</given-names></name>, &#x00026; <name name-style="western"><surname>Olson</surname><given-names>A. J.</given-names></name></person-group> (<year>2009</year>). <article-title>AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility</article-title>. <source><italic toggle="yes">Journal of Computational Chemistry</italic></source>, (<issue>16</issue>), <fpage>2785</fpage>&#x02013;<lpage>2791</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.21256</pub-id><pub-id pub-id-type="pmid">19399780</pub-id></mixed-citation></ref><ref id="CIT0037"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mounce</surname><given-names>B. C.</given-names></name>, <name name-style="western"><surname>Cesaro</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Carrau</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Vallet</surname><given-names>T.</given-names></name>, &#x00026; <name name-style="western"><surname>Vignuzzi</surname><given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>Curcumin inhibits Zika and chikungunya virus infection by inhibiting cell binding</article-title>. <source><italic toggle="yes">Antiviral Research</italic></source>, , <fpage>148</fpage>&#x02013;<lpage>157</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2017.03.014</pub-id></mixed-citation></ref><ref id="CIT0038"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muralidharan</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Sakthivel</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Velmurugan</surname><given-names>D.</given-names></name>, &#x00026; <name name-style="western"><surname>Gromiha</surname><given-names>M. M.</given-names></name></person-group> (<year>2020</year>). <article-title>Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure and Dynamics</italic></source>, <italic>38,</italic>&#x000a0;<fpage>1</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1752802</pub-id></mixed-citation></ref><ref id="CIT0039"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#x02019;Boyle</surname><given-names>N. M.</given-names></name>, <name name-style="western"><surname>Banck</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>James</surname><given-names>C. A.</given-names></name>, <name name-style="western"><surname>Morley</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Vandermeersch</surname><given-names>T.</given-names></name>, &#x00026; <name name-style="western"><surname>Hutchison</surname><given-names>G. R.</given-names></name></person-group> (<year>2011</year>). <article-title>Open Babel: An open chemical toolbox</article-title>. <source><italic toggle="yes">Journal of Cheminformatics</italic></source>, , <fpage>33</fpage>
<pub-id pub-id-type="doi">10.1186/1758-</pub-id>2946-3-33<pub-id pub-id-type="pmid">21982300</pub-id></mixed-citation></ref><ref id="CIT0040"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pettersen</surname><given-names>E. F.</given-names></name>, <name name-style="western"><surname>Goddard</surname><given-names>T. D.</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>C. C.</given-names></name>, <name name-style="western"><surname>Couch</surname><given-names>G. S.</given-names></name>, <name name-style="western"><surname>Greenblatt</surname><given-names>D. M.</given-names></name>, <name name-style="western"><surname>Meng</surname><given-names>E. C.</given-names></name>, &#x00026; <name name-style="western"><surname>Ferrin</surname><given-names>T. E.</given-names></name></person-group> (<year>2004</year>). <article-title>UCSF Chimera-a visualization system for exploratory research and analysis</article-title>. <source><italic toggle="yes">J Comput Chem</italic></source>, (<issue>13</issue>), <fpage>1605</fpage>&#x02013;<lpage>1612</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.20084</pub-id><pub-id pub-id-type="pmid">15264254</pub-id></mixed-citation></ref><ref id="CIT0041"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polansky</surname><given-names>H.</given-names></name>, &#x00026; <name name-style="western"><surname>Lori</surname><given-names>G.</given-names></name></person-group> (<year>2020</year>). <article-title>Coronavirus disease 2019 (COVID-19): first indication of efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 infection</article-title>. <source><italic toggle="yes">International Journal of Antimicrobial Agents</italic></source>, (<issue>6</issue>), <fpage>105971</fpage>
<pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105971</pub-id><pub-id pub-id-type="pmid">32283177</pub-id></mixed-citation></ref><ref id="CIT0042"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajtar</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Skalicka-Wo&#x0017a;niak</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>&#x0015a;wi&#x00105;tek</surname><given-names>&#x00141;.</given-names></name>, <name name-style="western"><surname>Stec</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Boguszewska</surname><given-names>A.</given-names></name>, &#x00026; <name name-style="western"><surname>Polz-Dacewicz</surname><given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>Antiviral effect of compounds derived from Angelica archangelica L. on Herpes simplex virus-1 and Coxsackievirus B3 infections</article-title>. <source><italic toggle="yes">Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association</italic></source>, (<issue>Pt 2</issue>), <fpage>1026</fpage>&#x02013;<lpage>1031</lpage>. <pub-id pub-id-type="doi">10.1016/j.fct.2017.05.011</pub-id><pub-id pub-id-type="pmid">28487231</pub-id></mixed-citation></ref><ref id="CIT0043"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Lou</surname><given-names>Z.</given-names></name>, &#x00026; <name name-style="western"><surname>Rao</surname><given-names>Z.</given-names></name></person-group> (<year>2013</year>). <article-title>The newly emerged SARS-Like coronavirus HCoV-EMC also has an &#x0201c;Achilles' heel&#x0201d;: current effective inhibitor targeting a 3C-like protease</article-title>. <source><italic toggle="yes">Protein &#x00026; Cell</italic></source>, (<issue>4</issue>), <fpage>248</fpage>&#x02013;<lpage>250</lpage>. <pub-id pub-id-type="doi">10.1007/s13238-013-2841-3</pub-id><pub-id pub-id-type="pmid">23549610</pub-id></mixed-citation></ref><ref id="CIT0044"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roe</surname><given-names>D. R.</given-names></name>, &#x00026; <name name-style="western"><surname>Cheatham</surname><given-names>T. E.</given-names></name></person-group> (<year>2013</year>). <article-title>PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data</article-title>. <source><italic toggle="yes">Journal of Chemical Theory and Computation</italic></source>, (<issue>7</issue>), <fpage>3084</fpage>&#x02013;<lpage>3095</lpage>. <pub-id pub-id-type="doi">10.1021/ct400341p</pub-id><pub-id pub-id-type="pmid">26583988</pub-id></mixed-citation></ref><ref id="CIT0045"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryckaert</surname><given-names>J. P.</given-names></name>, <name name-style="western"><surname>Ciccotti</surname><given-names>G.</given-names></name>, &#x00026; <name name-style="western"><surname>Berendsen</surname><given-names>H. J. C.</given-names></name></person-group> (<year>1977</year>). <article-title>Numerical integration of the cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes</article-title>. <source><italic toggle="yes">Journal of Computational Physics</italic></source>, (<issue>3</issue>), <fpage>327</fpage>&#x02013;<lpage>341</lpage>. <pub-id pub-id-type="doi">10.1016/0021-9991(77)90098-5</pub-id></mixed-citation></ref><ref id="CIT0046"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salem</surname><given-names>M. M.</given-names></name>, &#x00026; <name name-style="western"><surname>Werbovetz</surname><given-names>K. A.</given-names></name></person-group> (<year>2006</year>). <article-title>Isoflavonoids and other compounds from Psorothamnus arborescens with antiprotozoal activities</article-title>. <source><italic toggle="yes">Journal of Natural Products</italic></source>, (<issue>1</issue>), <fpage>43</fpage>&#x02013;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1021/np0502600</pub-id><pub-id pub-id-type="pmid">16441066</pub-id></mixed-citation></ref><ref id="CIT0047"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Modi</surname><given-names>P.</given-names></name>, &#x00026; <name name-style="western"><surname>Sagar</surname><given-names>S. R.</given-names></name></person-group> (<year>2020</year>). <article-title>In silico studies on therapeutic agents for COVID-19: Drug repurposing approach</article-title>. <source><italic toggle="yes">Life Sciences</italic></source>, , <fpage>117652</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2020.117652</pub-id><pub-id pub-id-type="pmid">32278693</pub-id></mixed-citation></ref><ref id="CIT0048"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shikishima</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Takaishi</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Honda</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Ito</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Takfda</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Kodzhimatov</surname><given-names>O. K.</given-names></name>, <name name-style="western"><surname>Ashurmetov</surname><given-names>O.</given-names></name>, &#x00026; <name name-style="western"><surname>Lee</surname><given-names>K. H.</given-names></name></person-group> (<year>2001</year>). <article-title>Chemical constituents of Prangos tschiniganica; structure elucidation and absolute configuration of coumarin and furanocoumarin derivatives with anti-HIV activity</article-title><source>. Chem. Pharm. Bull</source>, (<issue>7</issue>), <fpage>877</fpage>&#x02013;<lpage>880</lpage>. <pub-id pub-id-type="doi">10.1248/cpb.49.877</pub-id></mixed-citation></ref><ref id="CIT0049"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sinha</surname><given-names>S. K.</given-names></name>, <name name-style="western"><surname>Shakya</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Prasad</surname><given-names>S. K.</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Gurav</surname><given-names>N. S.</given-names></name>, <name name-style="western"><surname>Prasad</surname><given-names>R. S.</given-names></name>, &#x00026; <name name-style="western"><surname>Gurav</surname><given-names>S. S.</given-names></name></person-group> (<year>2020</year>). <article-title>An <italic>in-silico</italic> evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure and Dynamics</italic></source>, , <fpage>1</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1762741</pub-id></mixed-citation></ref><ref id="CIT0050"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>J. X.</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>Y. G.</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>J. B.</given-names></name>, <name name-style="western"><surname>Duan</surname><given-names>Z. B.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>W. K.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>Y. L.</given-names></name>, <name name-style="western"><surname>Lei</surname><given-names>H. M.</given-names></name>, &#x00026; <name name-style="western"><surname>Li</surname><given-names>H. Q.</given-names></name></person-group> (<year>2015</year>). <article-title>Antiviral activities of natural compounds derived from traditional chinese medicines against porcine circovirus type 2 (PCV2)</article-title>. <source><italic toggle="yes">Biotechnology and Bioprocess Engineering</italic></source>, (<issue>1</issue>), <fpage>180</fpage>&#x02013;<lpage>187</lpage>. <pub-id pub-id-type="doi">10.1007/s12257-014-0520-8</pub-id></mixed-citation></ref><ref id="CIT0051"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teague</surname><given-names>S. J.</given-names></name></person-group> (<year>2003</year>). <article-title>Implications of protein flexibility for drug discovery</article-title>. <source><italic toggle="yes">Nature Reviews. Drug Discovery</italic></source>, (<issue>7</issue>), <fpage>527</fpage>&#x02013;<lpage>541</lpage>. <pub-id pub-id-type="doi">10.1038/nrd1129</pub-id><pub-id pub-id-type="pmid">12838268</pub-id></mixed-citation></ref><ref id="CIT0052"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veckenstedt</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>G&#x000fc;ttner</surname><given-names>J.</given-names></name>, &#x00026; <name name-style="western"><surname>B&#x000e9;l&#x000e1;di</surname><given-names>I.</given-names></name></person-group> (<year>1987</year>). <article-title>Synergistic action of quercetin and murine alpha/beta interferon in the treatment of Mengo virus infection in mice</article-title>. <source><italic toggle="yes">Antiviral Research</italic></source>, (<issue>3</issue>), <fpage>169</fpage>&#x02013;<lpage>178</lpage>. <pub-id pub-id-type="doi">10.1016/0166-3542(87)90005-2</pub-id><pub-id pub-id-type="pmid">3038013</pub-id></mixed-citation></ref><ref id="CIT0053"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>von Rhein</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Weidner</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Hen&#x000df;</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Weber</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Sliva</surname><given-names>K.</given-names></name>, &#x00026; <name name-style="western"><surname>Schnierle</surname><given-names>B. S.</given-names></name></person-group> (<year>2016</year>). <article-title>Curcumin and Boswellia serrata gum resin extract inhibit chikungunya and vesicular stomatitis virus infections in&#x000a0;vitro</article-title>. <source><italic toggle="yes">Antiviral Research</italic></source>, , <fpage>51</fpage>&#x02013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2015.11.007</pub-id></mixed-citation></ref><ref id="CIT0054"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>K.</given-names></name>, &#x00026; <name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name></person-group> (<year>2016</year>). <article-title>Structure of Main Protease from Human Coronavirus NL63: Insights for Wide Spectrum Anti-Coronavirus Drug Design</article-title>. <source><italic toggle="yes">Scientific Reports</italic></source>, (<issue>1</issue>), <fpage>22677</fpage><pub-id pub-id-type="doi">10.1038/srep22677</pub-id><pub-id pub-id-type="pmid">26948040</pub-id></mixed-citation></ref><ref id="CIT0055"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Kollman</surname><given-names>P. A.</given-names></name>, &#x00026; <name name-style="western"><surname>Case</surname><given-names>D. A.</given-names></name></person-group> (<year>2006</year>). <article-title>Automatic atom type and bond type perception in molecular mechanical calculations</article-title>. <source><italic toggle="yes">Journal of Molecular Graphics &#x00026; Modelling</italic></source>, (<issue>2</issue>), <fpage>247</fpage>&#x02013;<lpage>260</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmgm.2005.12.005</pub-id><pub-id pub-id-type="pmid">16458552</pub-id></mixed-citation></ref><ref id="CIT0056"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Wolf</surname><given-names>R. M.</given-names></name>, <name name-style="western"><surname>Caldwell</surname><given-names>J. W.</given-names></name>, <name name-style="western"><surname>Kollman</surname><given-names>P. A.</given-names></name>, &#x00026; <name name-style="western"><surname>Case</surname><given-names>D. A.</given-names></name></person-group> (<year>2004</year>). <article-title>Development and testing of a general amber force field</article-title>. <source>J Comput Chem</source>, (<issue>9</issue>), <fpage>1157</fpage>&#x02013;<lpage>1174</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.20035</pub-id><pub-id pub-id-type="pmid">15116359</pub-id></mixed-citation></ref><ref id="CIT0057"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Xue</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Ding</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>X. C.</given-names></name>, <name name-style="western"><surname>Liao</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Bartlam</surname><given-names>M.</given-names></name>, &#x00026; <name name-style="western"><surname>Rao</surname><given-names>Z.</given-names></name></person-group> (<year>2008</year>). <article-title>Structures of two coronavirus main proteases: Implications for substrate binding and antiviral drug design</article-title>. <source><italic toggle="yes">Journal of Virology</italic></source>, (<issue>5</issue>), <fpage>2515</fpage>&#x02013;<lpage>2527</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02114-07</pub-id><pub-id pub-id-type="pmid">18094151</pub-id></mixed-citation></ref><ref id="CIT0058"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>M. S.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>J. M.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Chin</surname><given-names>Y. W.</given-names></name>, <name name-style="western"><surname>Jee</surname><given-names>J. G.</given-names></name>, <name name-style="western"><surname>Keum</surname><given-names>Y. S.</given-names></name>, &#x00026; <name name-style="western"><surname>Jeong</surname><given-names>Y. J.</given-names></name></person-group> (<year>2012</year>). <article-title>Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13</article-title>. <source><italic toggle="yes">Bioorganic &#x00026; Medicinal Chemistry Letters</italic></source>, (<issue>12</issue>), <fpage>4049</fpage>&#x02013;<lpage>4054</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2012.04.081</pub-id><pub-id pub-id-type="pmid">22578462</pub-id></mixed-citation></ref><ref id="CIT0059"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>G.</given-names></name>, &#x00026; <name name-style="western"><surname>Yan</surname><given-names>X.</given-names></name></person-group> (<year>2011</year>). <chapter-title>Volume 6 indexes</chapter-title> In <person-group person-group-type="editor"><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>G.</given-names></name>, &#x00026; <name name-style="western"><surname>Yan</surname><given-names>X.</given-names></name></person-group> (Eds.), <source><italic toggle="yes">Encyclopedia of traditional Chinese medicines - molecular structures, pharmacological activities, natural sources and applications</italic></source> (pp. <fpage>1</fpage>&#x02013;<lpage>730</lpage>). <publisher-name>Springer</publisher-name>
<pub-id pub-id-type="doi">10.1007/978-3-642-16744-7_1</pub-id></mixed-citation></ref></ref-list><glossary><def-list><title>Abbreviations</title><def-item><term>2D</term><def><p>Two-dimensional</p></def></def-item><def-item><term>3CL<sup>pro</sup></term><def><p>3-Chymotrypsin-like protease</p></def></def-item><def-item><term>3D</term><def><p>Three-dimensionsal</p></def></def-item><def-item><term>ADME</term><def><p>absorption, distribution, metabolism, and excretion</p></def></def-item><def-item><term>BBB</term><def><p>Blood Brain Barrier</p></def></def-item><def-item><term>COVID-19</term><def><p>Coronavirus Disease</p></def></def-item><def-item><term>GI</term><def><p>Gastrointestinal</p></def></def-item><def-item><term>hCoV</term><def><p>human coronavirus</p></def></def-item><def-item><term>HIV</term><def><p>human immunodeficiency virus</p></def></def-item><def-item><term>IFN</term><def><p>interferon</p></def></def-item><def-item><term>InChI</term><def><p>Inch key</p></def></def-item><def-item><term>MERS-CoV</term><def><p>Middle East respiratory syndrome- coronavirus</p></def></def-item><def-item><term>MlogP</term><def><p>lipophilicity</p></def></def-item><def-item><term>Mpro</term><def><p>Main protease domain</p></def></def-item><def-item><term>NSP</term><def><p>Non-structural proteins</p></def></def-item><def-item><term>NSP15</term><def><p>endoribonuclease</p></def></def-item><def-item><term>ORF</term><def><p>Open reading frame</p></def></def-item><def-item><term>PDB</term><def><p>Protein Data Bank</p></def></def-item><def-item><term>PL<sub>P</sub></term><def><p>papain-like protease</p></def></def-item><def-item><term>RMSD</term><def><p>Root mean square deviation</p></def></def-item><def-item><term>RMSF</term><def><p>Root mean square fluctuation</p></def></def-item><def-item><term>SASA</term><def><p>Solvent accessible surface area</p></def></def-item><def-item><term>RNA</term><def><p>Ribonucleic Acid</p></def></def-item><def-item><term>SARS-CoV</term><def><p>Severe acute respiratory syndrome- coronavirus</p></def></def-item><def-item><term>SARS-CoV-2</term><def><p>Severe acute respiratory syndrome-related coronavirus 2</p></def></def-item><def-item><term>SOPMA</term><def><p>Self-Optimized Prediction Method with Alignment</p></def></def-item><def-item><term>TPSA</term><def><p>Total Polar Surface Area</p></def></def-item><def-item><term>WHO</term><def><p>World Health Organization</p></def></def-item></def-list></glossary></back></article>